Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

March 12, 2024

https://www.globenewswire.com/news-release/2024/03/12/2844447/11676/en/Veru-Announces-the-Appointment-of-Louis-Aronne-MD-as-Chief-Medical-Advisor-for-its-Enobosarm-Program-for-High-Quality-Weight-Loss.html

MIAMI, March 12, 2024 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ:VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome (ARDS), today announced the appointment of Louis Aronne, MD, as Chief Medical Advisor and a member of the Scientific Advisory Board to support the advancement of enobosarm, an oral novel selective androgen receptor modulator (SARM), to avoid muscle loss and augment fat loss when combined with a Glucagon-like peptide-1 receptor agonist (GLP-1 RA) drug for potentially higher quality weight loss.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.